Ads
related to: opioid induced constipation medication list- Food and Diet Tips
Get Diet Tips and Recipes to Manage
Your Symptoms.
- Check Your Symptoms
Take A 5-Question Quiz To Learn
More About Your IBS-C Symptoms
- Side Effects
Learn About Common Side Effects And
What To Do If They Occur.
- FAQs
Read Through Commonly Asked
Questions About IBS-C/CIC.
- Food and Diet Tips
Search results
Results From The WOW.Com Content Network
Methylnaltrexone (MNTX, brand name Relistor), used in form of methylnaltrexone bromide (INN, USAN, BAN), is a medication that acts as a peripherally acting μ-opioid receptor antagonist that acts to reverse some of the side effects of opioid drugs such as constipation without significantly affecting pain relief or precipitating withdrawals.
Opioid drugs are known to cause opioid-induced constipation (OIC) by inhibiting gastric emptying and decreasing peristaltic waves leading to delayed absorption of medications and more water absorption from the feces. That can result in hard and dry stool and constipation for some patients. [2]
[128] [129] If encountered, rotation between several different opioid pain medications may decrease the development of increased pain. [130] [131] Opioid induced hyperalgesia more commonly occurs with chronic use or brief high doses but some research suggests that it may also occur with very low doses. [132] [133]
Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013 ORLANDO, Fla.--(BUSINESS WIRE)-- AstraZeneca (NYS: AZN) today ...
The closely related medication, methylnaltrexone (N-methylnaltrexone), is used to treat opioid-induced constipation but does not treat addiction as it does not cross the blood–brain barrier. Nalmefene (6-desoxy-6-methylenenaltrexone) is similar to naltrexone and is used for the same purposes as naltrexone.
Synergy Pharmaceuticals Announces Plans to Initiate a Phase 2 Study of SP-333 for Opioid-Induced Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NAS: SGYP) today announced ...